A new edition of industry news highlights focuses on health technology assessments (HTAs) and their growing acceptance of real world evidence (RWE). These industry highlights are published twice a month in The Journal of Comparative Effectiveness Research. “Read highlights from the latest […]
ISPOR Publishes 2021 Science Strategy, 8 Key HEOR Areas Identified Including RWE and HTA Research
ISPOR has published its Science Strategy as part of its Strategic Plan Update 2024. The purpose of the report is to identify ISPOR’s key areas for further research related to HEOR (health economics and outreach research). The eight areas identified in this report include utilizing RWE (real world […]
Virtual ISPOR 2021 Prerelease Session on HTAs in Clinical Trial Design
ISPOR will take place virtually from May 17th to 20th. Prerelease sessions will be available beginning on April 21st and available until June 30th, along with recordings from the conference. In a prerelease session moderated by Dr. Donna Messner, President and CEO of the Center for Medical […]
6 Recommendations Regarding HTAs in the United States
A whitepaper was recently released by researchers at the USC Schaeffer Center and the Aspen Institute. The authors discuss half a dozen recommendations relating to HTAs (Health Technology Assessments) in the United States, which could lead to changes in the pricing of prescription drugs. […]
ICER Releases Draft Evidence Report on Therapies for Lupus Nephritis
Also this morning, we published our Draft Evidence Report assessing the comparative clinical effectiveness and value of voclosporin (Aurinia Pharmaceuticals) and belimumab (Benlysta®, GlaxoSmithKline) for the treatment of lupus nephritis. We’re now accepting public comments through February […]
ICER Seeks Applications for New Health Technology Assessment Fellowship
The Institute for Clinical and Economic Review (ICER) is now accepting applications for the inaugural cycle of a new Health Technology Assessment (HTA) Fellowship. The ICER HTA Fellowship is a paid full-time one-year program for post-master's and post-doctoral graduates that provides experiential […]
NICE Updates Methods for Health Technology Evaluations
On November 6, 2020, NICE published a summary of its proposed changes to health technology evaluation methods. NICE periodically assesses its methods to optimize the process and ensure it can support rapid access to clinically- and cost-effective technologies. Within the scope of this process, […]
What’s Driving Oncology HTAs in South Korea?
Reimbursement in South Korea depends upon a favorable review by Health Insurance Review Agency (HIRA), and some therapies may not be reimbursed because of shortcomings from the perspective of HIRA. To help pharma companies plan clinical trials and economic evidence submission in order to achieve […]
Response to NICE Methods of Health Technology Evaluation
NICE recently posted a consultation entitled "The NICE methods of health technology evaluation: the case for change". which detailed its proposals for reviewing and/or updating its methods. It sets out 5 areas of work with 56 separate proposals listed separately across these sections. These […]
The NICE methods of health technology evaluation: the case for change
NICE recently posted a consultation entitled "The NICE methods of health technology evaluation: the case for change" which details its proposals for reviewing and/or updating its methods. It sets out 5 areas of work with 56 separate proposals listed separately across these sections. These proposals […]
